Ultima-CJC-1295 With DAC 2 mg

Manufacturer: Ultima Pharmaceuticals

Pharmaceutical name: Modified GRF (1-29)

Pack: 1 vial (2 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic version that resembles part of the naturally occurring growth hormone releasing hormone (GHRH). The chemistry of CJC-1295 with DAC is centered on the first 29 amino acids of GHRH, as these initial amino acids ensure complete biological efficacy.

 

However, this peptide has undergone further modifications by altering four amino acids to enhance its stability and effectiveness compared to the original CJC-1295 without DAC. These four amino acids enable the peptide to form a permanent bond with the protein albumin in the body, which minimizes degradation and oxidation, thereby increasing stability. Additionally, these modified amino acids enhance the binding affinity to the GHRH receptor, boosting potency. GHRH is essential for the natural secretion of growth hormone and is crucial for achieving optimal growth during development.

 

CJC-1295 promotes growth hormone release by attaching to GHRH receptors, which should stimulate the secretion of the various growth hormone peptides typically released by the pituitary gland. This stimulation will lead to increases in bone density and collagen synthesis, along with enhancements to the immune response. Furthermore, it will encourage the development of lean muscle mass.

 

CJC-1295 with DAC can be paired with growth hormone releasing peptides to enhance the effects of peptide cycling. CJC-1295 DAC is commonly combined with growth hormone replacement peptides (GHRP) 6 or GHRP-2. Using CJC-1295 DAC in conjunction with GHRPs will accelerate fat and weight loss while stimulating anabolic effects through growth hormone-induced fat breakdown. Overall, CJC-1295 with DAC will promote protein synthesis and support the development of lean muscle tissue. The peptide also aids in quicker injury recovery, reduces body fat, and increases muscle mass. Its growth-promoting effects will encourage cell growth and division, enhancing skin health, healing, and immune system functionality.

 

This peptide should not be mistaken for CJC-1295 without DAC, as the chemical characteristics differ significantly and will impact dosing. CJC-1295 DAC has an approximate half-life of 8 days after injection. Subcutaneous injections of CJC-1295 with DAC should occur once a week at doses of either 100 mcg or 200 mcg due to its prolonged half-life. This CJC-1295 DAC peptide cycling method will result in a sustained overall increase in growth hormone. A weekly dose of CJC-1295 with DAC can be stacked with other GHRPs, such as GHRP-6 or GHRP-2.

 

Numerous studies have documented the growth-enhancing effects and safety of administering GHRH to children with growth hormone deficiency. Various treatment methods, including intravenous pulses, intranasal delivery, subcutaneous injections, and continuous infusion, have been investigated, showing that the growth-promoting effects of GHRH correlate with the dosage and frequency of administration. No unanticipated adverse reactions have occurred after prolonged use, irrespective of the delivery method. However, minor side effects may manifest, such as fatigue, euphoria (head rush), water retention, and sensations of tingling and numbness. Adhering to the recommended dosages will help minimize the risk of side effects.